NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

March 6, 2018

Study Completion Date

March 6, 2018

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL

VRC-CHKVLP059-00-VP

VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).

OTHER

VRC-PBSPLA043-00-VP

VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.

Trial Locations (6)

Unknown

Instituto Dermatológico y Cirugía de Piel, Santo Domingo

University Hospital of Pointe-à-Pitre, Pointe-à-Pitre

Centres GHESKIO, Port-au-Prince

0596 55 20 00

Centre Hospitalier Universitaire (CHU), Martinique, Fort-de-France

00935

San Juan Hospital, Research Unit, Rio Piedras

00936-5067

Puerto Rico Clinical and Translational Research Consortium, San Juan

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH